2006年3月27日，欧洲药品管理局（EMEA）发布消息，在完成了对他克莫司（Tacrolimus）和匹美莫司（Pimecrolimus）的安全性评价后，EMEA的人用医药产品委员会（CHMP）公布了评价结果：他克莫司和匹美莫司的效益大于风险，但必须谨慎使用，以最大...
基于12个网页-相关网页
Pimecrolimus Cream 吡美莫司乳膏
According to the patent literature, we improved and simplified the response route, and reduce costs; pimecrolimus yield: 42.1%, the purity > 96%, mp 135.2-136.1℃, according to the data above, the product is confirmed to be pimecrolimus.
对专利文献方法进行了改进,提高了收率,降低了成本;吡美莫司的总收率42.1%,纯度>96%,熔点为135.2-136.1℃,与文献报道相符。
参考来源 - FK520的分离及其衍生物的合成·2,447,543篇论文数据，部分数据来源于NoteExpress
As expected, pimecrolimus was well tolerated, the team reports, noting that there were no drug-related serious adverse effects.
与预料一样，吡美莫司耐受性良好，该研究小组指出，吡美莫司没有严重的副作用。
Stopping pimecrolimus cream did not lead to a rebound of skin symptoms in most of the patients who entered the follow-up phase, they also report.
该小组也报道指出停用吡美莫司乳膏并不会导致随访期患者皮肤症状反弹。
Pimecrolimus was most effective in patients with corticosteroid-induced POD. Pimecrolimus-treated patients reported greater gains in quality of life than control-treated patients.
吡美莫司治疗皮质类固醇激素诱导的口周皮炎患者尤为有效。吡美莫司治疗的患者生活质量改善比对照组多。
应用推荐